Suchergebnisse - "YO603Y8113"

PubPharm (112)

1

Plasma Concentrations of Rosmarinic Acid in Patients on Antiretroviral Therapy : In Silico Exploration Based on Clinical Data

enthalten in: International journal of molecular sciences | 2024

von Hitl, M. | Pavlović, N. | Brkić, S. | +3

2

Long-term outcomes of highly experienced people with HIV undergoing salvage therapy with raltegravir

enthalten in: Medicine | 2023

von Patiño Escarcina, J. | Netto, E. | Brites, C.

3

Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV : A Systematic Review

enthalten in: Clinical pharmacokinetics | 2023

von Toledo, T. | Castro, T. | Oliveira, V. | +5

4

PRESTIGIO RING : "A 59-year-old HIV-1 positive, highly treatment-experienced woman failing darunavir/ ritonavir plus raltegravir"

enthalten in: The new microbiologica | 2023

von Labate, L. | Bruzzone, B. | Spagnuolo, V. | +4

5

Long-term follow-up of HIV-1 multi-drug-resistant treatment-experienced participants treated with etravirine, raltegravir and boosted darunavir : towards drug-reduced regimen? ANRS CO3 Aquitaine Cohort 2007-2018

enthalten in: International journal of antimicrobial agents | 2023

von Nyamankolly, E. | Bellecave, P. | Wittkop, L. | +11

6

Transfer of antiretroviral drugs into breastmilk : a prospective study from the Swiss Mother and Child HIV Cohort Study

enthalten in: The Journal of antimicrobial chemotherapy | 2022

von Aebi-Popp, K. | Kahlert, C. | Crisinel, P. | +58

7

Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States

enthalten in: The New England journal of medicine | 2022

von Patel, K. | Huo, Y. | Jao, J. | +114

8

Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America : a cohort study

enthalten in: The lancet. HIV | 2022

von Trickey, A. | Zhang, L. | Gill, M. | +23

CommentIn: Lancet HIV. 2022 Jun;9(6):e371-e372. - PMID 35659330

9

Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings : ACTG A5288 strategy trial

enthalten in: Journal of the International AIDS Society | 2022

von Avihingsanon, A. | Hughes, M. | Salata, R. | +31

10

Changes in lipidomic profile by anti-retroviral treatment regimen : An ACTG 5257 ancillary study

enthalten in: Medicine | 2021

von Chaudhary, N. | Kind, T. | Willig, A. | +6

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[12]